• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

MassDevice Earnings Roundup

Bellerophon shares fall despite Street-beating Q2 results

August 7, 2017 By Sarah Faulkner

Bellerophon Therapeutics

Shares in Bellerophon Therapeutics (NSDQ:BLPH) fell today even though the company beat expectations on Wall Street with its second quarter results. The Warren, N.J.-based company posted a net loss of -$3.9 million with no sales for the 3 months ended June 30, for bottom-line growth of 23% compared with the same period last year. Adjusted to […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Vascular, Wall Street Beat Tagged With: Bellerophon Therapeutics

Pulmatrix beats Q2 EPS by a penny

August 7, 2017 By Sarah Faulkner

Pulmatrix

Shares in Pulmatrix (NSDQ:PULM) fell last week even though the biopharmaceutical company beat expectations on Wall Street with its second quarter results. The Lexington, Mass.-based company posted a net loss of -$5.6 million with no revenue for the 3 months ended June 30, for bottom-line growth of 39% compared with the same period last year. Adjusted […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Pulmatrix Inc.

Cerus posts Street-beating Q2 results

August 4, 2017 By Sarah Faulkner

Cerus Corp.

Shares in Cerus (NSDQ:CERS) fell today despite the company beating expectations on Wall Street with its second quarter results. The Concord, Calif.-based company posted a net loss of -$17.1, or -16¢ per share, on sales of $9.5 million for the 3 months ended June 30, for bottom-line growth of 6% on sales growth of 3% compared […]

Filed Under: Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Cerus Corporation

Insulet Q2 sales tops estimates

August 4, 2017 By Sarah Faulkner

Insulet

Shares in Insulet (NSDQ:PODD)  rose today after the company met earnings expectations on Wall Street and beat sales estimates with its second quarter results. The Billerica, Mass.-based company posted a net loss of -$7.8 million, or -13¢ per share, on sales of $109.8 million for the 3 months ended June 30, for bottom-line loss of -85% […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Insulet

Glaukos shares fall on Q2 sales, EPS miss

August 3, 2017 By Fink Densford

Glaukos logo

Shares in Glaukos (NYSE:GKOS) have fallen today after the diabetes-focused medical device maker missed expectation on Wall Street with its 2nd quarter earnings results. The San Clemente, Calif.-based company posted losses of $3.3 million, or 10¢ per share, on sales of $41.3 million for the 3 months ended June 30, seeing profits swing 241.6% into losses […]

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Glaukos

Teva lowers outlook after Q2 EPS misses estimates

August 3, 2017 By Sarah Faulkner

Teva Pharmaceutical

(Reuters) – Israeli drugs group Teva Pharmaceuticals (NYSE:TEVA) reported a steeper than expected drop in second-quarter earnings on Thursday, due to weaker prices in the United States, and cut its interim dividend by 75 percent. Along with a substantial reduction in its 2017 outlook, shares in the world’s largest generics drugmaker tumbled 16.5 percent in Tel Aviv […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Teva Pharmaceuticals

Pacira misses on Q2 sales, earnings

August 2, 2017 By Sarah Faulkner

Pacira Pharmaceuticals

Shares in Pacira Pharmaceuticals (NSDQ:PCRX) fell slightly today after the pharmaceutical company missed expectations on Wall Street with its second quarter results. The Parsippany, N.J.-based company posted a net loss of -$19.7 million, or -49¢ per share, on sales of $70.9 million for the 3 months ended June 30, for bottom-line loss of -148% on sales […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Pacira Pharmaceuticals

Aerie Pharmaceuticals misses Q2 EPS by a penny

August 2, 2017 By Sarah Faulkner

Aerie

Shares in Aerie Pharmaceuticals (NSDQ:AERI) held steady today after the pharmaceutical company missed EPS estimates on Wall Street with its second quarter results. The Irvine, Calif.-based company posted a net loss of -$28.4 million, or -82¢ per share, with its bottom line down -22.5% compared with the same period last year. Adjusted to exclude 1-time items, […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals

Intersect ENT tops EPS, sales estimates in Q2

August 2, 2017 By Sarah Faulkner

Intersect ENT

Shares in Intersect ENT (NSDQ:XENT) surged today after the drug-device company beat expectations on Wall Street with its second quarter results. The Menlo Park, Calif.-based company posted a loss of -$2.3 million on sales of $24 million for the 3 months ended June 30, for bottom-line growth of 62% on sales growth of 24% compared […]

Filed Under: Drug-Device Combinations, Featured, Implants, MassDevice Earnings Roundup, Otolaryngology Ear, Nose & Throat, Wall Street Beat Tagged With: Intersect ENT Inc.

Awaiting tax reform clarity, Pfizer delays potential M&A

August 1, 2017 By Sarah Faulkner

Pfizer

(Reuters) – Pfizer‘s (NYSE:PFE) chief executive said on Tuesday he would prefer to wait for clarity on U.S. tax reform before engaging in any big deals in order to get a better understanding of any potential acquisition target’s value. The largest U.S. drugmaker has been under increasing pressure from investors and Wall Street to pull […]

Filed Under: Featured, MassDevice Earnings Roundup, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Bristol-Myers Squibb Co., Pfizer Inc.

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Page 32
  • Interim pages omitted …
  • Page 38
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS